Literature DB >> 16338749

Cerebrospinal fluid proteomics and human immunodeficiency virus dementia: preliminary observations.

Joseph R Berger1, Malcolm Avison, Yunanan Mootoor, Carol Beach.   

Abstract

Protein profiling using mass spectrometry may be useful in identifying previously unknown protein markers in human immunodeficiency virus (HIV) dementia and provide insight into disease pathogenesis. Six samples of matched cerebrospinal (CSF) and blood serum from patients with no, mild, and moderate dementia were prepped for biomarker screening by the Ciphergen system. Chips were analyzed in the matrix-assisted laser desorption/ionization (MALDI) mass spectrometer at low mass (700 to 20,000 Da) and at higher mass (5000 to 100,000 Da). In both serum and CSF samples, differences in protein intensity appeared to correlate with degree of dementia. This preliminary study suggests that protein markers of HIV dementia may be detected by MALDI mass spectrometry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16338749     DOI: 10.1080/13550280500385237

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  13 in total

Review 1.  Proteome analysis by mass spectrometry.

Authors:  P Lee Ferguson; Richard D Smith
Journal:  Annu Rev Biophys Biomol Struct       Date:  2003-01-28

2.  Proteomics analysis of human astrocytes expressing the HIV protein Tat.

Authors:  Chava B Pocernich; Debra Boyd-Kimball; H Fai Poon; Visith Thongboonkerd; Bert C Lynn; Jon B Klein; Vittorio Calebrese; Avindra Nath; D Allan Butterfield
Journal:  Brain Res Mol Brain Res       Date:  2005-02-18

3.  Proteomic analysis of oxidatively modified proteins induced by the mitochondrial toxin 3-nitropropionic acid in human astrocytes expressing the HIV protein tat.

Authors:  Chava B Pocernich; H Fai Poon; Debra Boyd-Kimball; Bert C Lynn; Avindra Nath; Jon B Klein; D Allan Butterfield
Journal:  Brain Res Mol Brain Res       Date:  2005-02-18

Review 4.  The use of proteomics for the assessment of clinical samples in research.

Authors:  Sarah Aldred; Melissa M Grant; Helen R Griffiths
Journal:  Clin Biochem       Date:  2004-11       Impact factor: 3.281

5.  Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease.

Authors:  Pawel Ciborowski; Yoshimi Enose; Andrea Mack; Melissa Fladseth; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2004-12       Impact factor: 3.478

Review 6.  Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection.

Authors:  Yuri Persidsky; Howard E Gendelman
Journal:  J Leukoc Biol       Date:  2003-11       Impact factor: 4.962

7.  The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study.

Authors:  J C McArthur; T E Nance-Sproson; D E Griffin; D Hoover; O A Selnes; E N Miller; J B Margolick; B A Cohen; H Farzadegan; A Saah
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment.

Authors:  X Luo; K A Carlson; V Wojna; R Mayo; T M Biskup; J Stoner; J Anderson; H E Gendelman; L M Meléndez
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

9.  Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response.

Authors:  P Brouwers; M P Heyes; H A Moss; P L Wolters; D G Poplack; S P Markey; P A Pizzo
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

10.  Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study.

Authors:  Valerie Wojna; Kimberly A Carlson; Xiaoguang Luo; Raúl Mayo; Loyda M Meléndez; Edmundo Kraiselburd; Howard E Gendelman
Journal:  J Neurovirol       Date:  2004       Impact factor: 2.643

View more
  8 in total

1.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

2.  Biomarkers of neurological status in HIV infection: a 3-year study.

Authors:  Ann B Ragin; Ying Wu; Renee Ochs; Rachel Scheidegger; Bruce A Cohen; Robert R Edelman; Leon G Epstein; Justin McArthur
Journal:  Proteomics Clin Appl       Date:  2010-01-04       Impact factor: 3.494

Review 3.  Human body fluid proteome analysis.

Authors:  Shen Hu; Joseph A Loo; David T Wong
Journal:  Proteomics       Date:  2006-12       Impact factor: 3.984

4.  CSF proteomic fingerprints for HIV-associated cognitive impairment.

Authors:  Juliana Pérez Laspiur; Eric R Anderson; Pawel Ciborowski; Valerie Wojna; Wojciech Rozek; Fenghai Duan; Raul Mayo; Elaine Rodríguez; Marinés Plaud-Valentín; José Rodríguez-Orengo; Howard E Gendelman; Loyda M Meléndez
Journal:  J Neuroimmunol       Date:  2007-10-22       Impact factor: 3.478

5.  Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys.

Authors:  Gurudutt Pendyala; Sunia A Trauger; Ewa Kalisiak; Ronald J Ellis; Gary Siuzdak; Howard S Fox
Journal:  J Proteome Res       Date:  2009-05       Impact factor: 4.466

6.  YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor.

Authors:  Dafna Bonneh-Barkay; Stephanie J Bissel; Gouji Wang; Kenneth N Fish; Georgina C B Nicholl; Samuel W Darko; Rafael Medina-Flores; Michael Murphey-Corb; Premeela A Rajakumar; Julia Nyaundi; John W Mellors; Robert Bowser; Clayton A Wiley
Journal:  Am J Pathol       Date:  2008-06-13       Impact factor: 4.307

7.  Biomarkers in chronic adult hydrocephalus.

Authors:  Andrew Tarnaris; Laurence D Watkins; Neil D Kitchen
Journal:  Cerebrospinal Fluid Res       Date:  2006-10-04

Review 8.  Proteomics, biomarkers, and HIV-1: A current perspective.

Authors:  Maire Rose Donnelly; Pawel Ciborowski
Journal:  Proteomics Clin Appl       Date:  2015-07-08       Impact factor: 3.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.